



Financial Tear Sheet

Corporate Profile

Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, for the treatment of sickle cell disease and idiopathic pulmonary fibrosis.

Primary IR Contact

Myesha Edwards

Phone: 650-351-4730

E-mail:

investor@globalbloodtx.com

Stock Performance

GBT (Common Stock)

Exchange NASDAQ GS (US Dollar)

Price **\$32.55**

Change (%) ▲ 0.55 (1.72%)

Volume 674,181

52 Week Low \$13.35


Market Cap \$1,421,679,970

Rolling EPS -2.47

PE Ratio 0

Shares Outstanding 43,676,804

Data as of 10/20/17 4:00 p.m. ET



Recent Headlines & Events

10/11/17

[Global Blood Therapeutics Announces Presentation of New Data Showing Positive Effect of GBT440 on Sickle Cell Disease Patient with Variant Genotype](#)

10/03/17

[Global Blood Therapeutics Announces Upcoming Presentations of GBT440 Data at Two Sickle Cell Disease Meetings in October](#)

09/26/17

[Global Blood Therapeutics Announces New Employment Inducement Grants](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
10/18/17	<u>4</u>
10/11/17	<u>8-K</u>
10/05/17	<u>4</u>
10/03/17	<u>SC 13G</u>

Corporate Governance

[Ted W. Love, M.D.](#) Chief Executive Officer

[Jeffrey Farrow](#) Chief Financial Officer

[Jung E. Choi](#) Chief Business and Strategy Officer

[Tricia Suvari](#) Chief Legal Officer

[Hing Sham, Ph.D.](#) Senior Vice President, Research

[Peter Radovich](#) Vice President, Program Leadership and Business Strategy

Data provided by Nasdaq. Minimum 15 minutes delayed.